Development of 3DMPUS as a Decision Support Tool for Patients With Liver Tumors Undergoing Therapy

This clinical trial studies how well 3-dimensional multi-parametric ultrasound (3D MPUS) imaging works as a decision-support tool for patients with liver tumors undergoing therapy. Continuous and dynamic imaging of patients undergoing therapy is required to monitor early-phase treatment response. 3D-MPUS is an inexpensive and safe method, which may provide complementary quantitative functional (perfusion) and tissue characterization information to anatomical radiological assessment or blood biomarkers.

Inclusion Criteria:The participant is about to undergo a new course of therapy for primary or metastatic liver cancer.The participant is age > 18 years.Participant has at least one target lesion (≥1cm and <14cm)The participant is willing to comply with protocol requirements.The participant has the ability to understand and the willingness to sign a written informed consent document.Exclusion Criteria:Participant has documented anaphylactic or other severe reactions to any ultrasound or CT contrast media.Participant has documented severe Hypersensitivity to macrogol/ polyethylene glycol (PEG).Participant has documented the presence of a cardiac shunt or pulmonary hypertension (pulmonary artery pressure >90 mmHg).Participant has documented renal insufficiency with a creatinine level of >1.5mg/dl.Participant has documented uncontrolled systemic hypertension.Participant has documented concomitant diseases like acute endocarditis, prosthetic valve, hyperactive coagulation states and/ or recent thromboembolism, and sepsisParticipant is pregnant (positive urine or serum beta-hCG) or lactating.